Published in final edited form as:

Cancer Epidemiol Biomarkers Prev. 2018 May ; 27(5): 558–565. doi:10.1158/1055-9965.EPI-17-0722.

Exogenous Hormone Use and Endometrial Cancer in U.S. Black Women

Todd R. Sponholtz¹, Julie R. Palmer^{2,3}, Lynn A. Rosenberg^{2,3}, Elizabeth E. Hatch³, Lucile L. Adams-Campbell⁴, and Lauren A. Wise^{2,3}

¹Section of Preventive Medicine and Epidemiology, Boston University School of Medicine, 801 Massachusetts Ave, Suite 470, Boston, MA 02118

²Slone Epidemiology Center, Boston University, 72 East Concord Street, L-7, Boston, MA 02118, USA

³Department of Epidemiology, Boston University School of Public Health, 715 Albany Street, The Talbot Building, T2C, Boston, MA 02118

⁴Lombardi Cancer Center, Georgetown University, 3800 Reservoir Road, N.W., Washington D.C., USA

Abstract

Background—Although endometrial cancer risk differs among white and black women, few data on its associations with exogenous hormone use in the latter group are available. Studies have reported lower endometrial cancer risk among users of oral contraceptives (OC), but higher risk among users of estrogen-only female menopausal hormones (FMH). Evidence for the risk among estrogen plus progestin FMHs users is equivocal.

Methods—We followed 47,555 Black Women's Health Study participants with an intact uterus from 1995 through 2013. Data on exogenous hormone use, covariates, and endometrial cancer were obtained biennially. Self-reported incident cases of endometrial cancer were confirmed by medical records or cancer registries whenever possible. We estimated incidence rate ratios (IRR) and 95% confidence intervals (CI) using Cox proportional hazards regression.

Results—We observed 300 endometrial cancer cases during 689,546 person-years of follow-up. Compared with never use, 10 years' duration of OC use was associated with lower risk (multivariable IRR=0.45, 95% CI=0.27, 0.74), but risk was higher among current users of estrogen-only- (IRR=3.72, 95% CI=1.67, 8.30) and estrogen plus progestin FMH (IRR=1.55, 95% CI=0.77, 3.10). Risk was not increased among former users of estrogen-only (IRR=0.85, 95% CI=0.43, 1.68) or estrogen plus progestin FMH (IRR=0.62, 95% CI=0.36, 1.08).

Conclusions—Current use of estrogen-only- and estrogen plus progestin FMH was associated with increased risk of endometrial cancer. Risk appeared lower among former users of estrogen plus progestin FMH. Long term OC use was associated with reduced risk.

Impact—Our results are generally consistent with those among white women.

Keywords

Endometrial cancer; African American women; oral contraceptives

INTRODUCTION

The risk of endometrial cancer, which has the highest incidence among gynecologic cancers and the fourth highest incidence among women in the US (1), is thought to depend primarily upon exposure of the endometrium to estrogens and progesterone (2). Estrogens, which spur the proliferation of endometrial tissue, are associated with increased risk (2). Conversely, progesterone blocks the activity of estrogens and is associated with decreased risk (2).

Most epidemiologic studies have found an inverse association between the use of oral contraceptives (OCs) and endometrial cancer (3–13), although one reported a positive association (14). Stronger inverse associations have been reported for longer durations of use (4–9, 13), which may continue at least 20 years after cessation (9, 11). The association of OC use with endometrial cancer does not appear to vary according to the potency of estrogen or progestins used (10, 13). The association between various formulations female menopausal hormones (FMH) and endometrial cancer has been extensively studied (reviewed (15)). Use of estrogen-only FMH has been consistently associated with increased endometrial cancer risk (16–23). Relative risks range from 2.0 to 10.0 for long-term use (generally 5 or 10 years) (18–20, 22). Progestins were added to FMH formulations to reduce the risk of endometrial cancer. The earliest formulations of these drugs administered estrogens and progestins sequentially, with progestins taken for one to three weeks every month. Studies of sequential FMHs have been inconsistent, with reports of increased risk (18, 19, 22–25) or no association with endometrial cancer (20). Most studies have found that FMH formulations in which progestins are taken continuously decrease risk (4, 16, 20, 22–27), but one observed a positive association (19).

To our knowledge, no studies of endometrial cancer and FMH have reported race-specific estimates. Because black women have a higher prevalence of obesity and obesity may modify the association between FMH and endometrial cancer (16, 17, 20, 21, 23), it is of interest to examine association of FMH with risk of endometrial cancer in this population. In order to contribute to the body of evidence regarding use of exogenous hormones and risk of endometrial cancer in black women, we evaluated these relationships in the Black Women's Health Study, a US-based prospective cohort study.

METHODS

Data Source

The Black Women's Health Study (BWHS) is a cohort study which has followed 59,001 self-identified black women since its inception in 1995 (28). Women aged 21–69 were identified from a list of *Essence* magazine subscribers, black professional organizations, and friends and relatives of study participants and enrolled via mailed questionnaires. At

baseline, participants provided data on demographic factors, reproductive history, health history tobacco and alcohol use, anthropometric measurements and other factors. Participants complete follow-up questionnaires every two years to update outcome, exposure, and covariate data. As of 2013, follow-up is complete for approximately 87% of potential person-years. All participants provided written informed consent, and the study protocol was approved by the Boston University Institutional Review Board.

Women reporting a history of uterine cancer ($n=258$), cervical cancer ($n=82$), or hysterectomy ($n=10,659$), and those from whom no follow-up questionnaire has been received ($n=447$) were excluded from this analysis. The analytic sample comprised the remaining 47,555 women who were followed for incident endometrial cancer from 1995 through 2013.

Outcome Ascertainment

A total of 354 potential cases were identified by self-report of new diagnoses of “uterine cancer” on biennial follow-up questionnaires from 1997 through 2013 or through state cancer registries in 24 states where 95% of participants lived. Eighteen women subsequently reported that they had a condition other than uterine cancer when contacted for permission to release medical records, 18 were disconfirmed by medical record, 231 were confirmed as either endometrial cancer ($n=213$) or uterine sarcoma ($n=18$), and records could not be obtained for 87. Due to the high confirmation rate, we included the 87 unverified cases in the analysis. After uterine sarcomas were excluded, 300 cases of endometrial cancer were available for study. International Classification of Diseases for Oncology (ICD-O) codes were available to allow 188 of the confirmed cases to be classified by histological type; 136 (72%) were classified as type I (ICD-O codes 8010, 8020, 8140, 8210, 8255, 8260, 8262, 8263, 8380, 8382, 8383, 8440, 8480, 8481, 8570), and 51 as other histologic types (ICD-O codes 8041, 8050, 8070, 8071, 8072, 8310, 8323, 8441, 8460, 8461, 8560, 8950, 8951, 8980).

Exposure Ascertainment

At baseline, women were asked if they had ever used OCs and the duration of use for each age between 13 and “45 or more”. Choices included <6, 6-9, or 10 months. On subsequent questionnaires, they indicated if they had used OCs since the previous questionnaire, as well as the duration of use during that time period (choose <6, 6-11, 12-17, or 18 months in 1997, 1999, and 2001; fill in number of months in 2003, 2005, 2007, 2009, 2011, and 2013).

In 1995, women reported whether or not they had ever used replacement female hormones for menopause, when they last took them (current user, <1, 1-2, 3 years ago), how many years they took them (<1, 1, 2, 3-4, 5-6, 7-9, 10-14, 15 years) and the name and type of hormone used most recently. Women who reported progestin use were asked about their pattern of use (used continuously, 2-3 weeks each month, <2 weeks each month, other pattern of use). Follow-up questionnaires asked whether they had used estrogen replacement therapy since the last questionnaire, the duration of use during that period (choose <6, 6-11, 12-17, or 18 months in 1997, 1999, and 2001; fill in number of months in 2003, 2005, 2007, 2009, 2011, and 2013), and the name and type of hormone used most recently. Data

on pattern of progestin use among estrogen plus progestin FMH users was not collected after the baseline questionnaire. Use of estrogen vaginal cream was not considered exposure to estrogen-only FMH.

Covariates

Women reported their age at menarche, education level, and weight at age 18 on the baseline questionnaire in 1995. Data on height and current weight (with which we computed BMI) and physician-diagnosed diabetes, age at first birth, parity, gynecologic surgeries (hysterectomy, bilateral oophorectomy, unilateral oophorectomy), and menopausal status were collected at baseline and updated on subsequent biennial follow-up questionnaires. Menopause was defined as the absence of menstrual periods within the last 12 months. We classified women whose menopausal status was unknown according to the distribution of age at natural menopause in the BWHs. They were classified as premenopausal if their current age was below the 10th percentile (43 years) postmenopausal if their current age was greater than the 90th percentile (56 years) and unknown status if current age was 43-56 years (29). Data on vigorous exercise (hours/week) were collected on every questionnaire except 2003 and 2005. Marital status was reported in 1995, 1997, 1999 and 2003.

Data Analysis

We calculated person-time from baseline until the first occurrence of one the following events: diagnosis of endometrial cancer, diagnosis of non-epithelial uterine cancer, hysterectomy, loss-to-follow-up, or the end of follow-up (2013). Age- and questionnaire cycle-stratified Cox proportional hazards regression models (30) were used to estimate crude and adjusted IRRs and 95% confidence intervals (CI) for all categories of exposure compared with the reference category. Because data on the timing of progestin use in estrogen plus progestin FMH user was available only at baseline, this variable was analyzed as a time-invariant Cox model using baseline data. The Andersen-Gill data structure (31) was used to update time-varying covariates for all other exposures. Missing values were imputed by carrying forward the last observation. Departures from proportional hazards were assessed by comparing models with and without interaction terms between exposures and each of the time scales (age and questionnaire cycle) using the likelihood ratio test.

Time-varying variables were defined similarly for OCs and FMH. Ever use was defined as a report on the current or any prior questionnaire. An ever user was classified as a current user if she reported any use since the last questionnaire, otherwise she was classified as a former user. Recency and duration of use were determined at baseline and updated whenever a woman reported use since the prior questionnaire.

For OCs, duration of use was categorized as (0, 1-4, 5-9, and 10 years). Recency of use was categorized as (never user, current user, 1-9, 10-19, 20-29, 30 years since last use). We also cross-tabulated recency and duration of use in categories, comparing never users to each combination of duration (1-4, 5 years) and recency (1-9, 10-19, 20 years). For FMH, duration was categorized as (0, 1-4, 5 years) and recency as (never user, current user, 1-9, 10 years).

In order to control for confounding, we adjusted for the following known or suspected risk factors for endometrial cancer: age at menarche (<11, 11, 12-13, 14 years), parity (parous, nulliparous), smoking status (never, former, current), vigorous physical activity (0, 1-4, 5 hours/week), and BMI (<25, 25-29, 30-34, 35-39, 40 kg/m²). Models were mutually adjusted for OC use (never, former, current) and use of estrogen-only and estrogen plus progestin FMH (never, former, current), when appropriate. In analyses of OC use, we additionally adjusted for menopausal status (premenopausal, postmenopausal, unknown status). We further examined potential confounding by BMI at age 18, history of infertility, income and marital status. Inclusion of these variables did not change effect estimates appreciably (<10%), and they were omitted from the final models.

Young women are at low risk for endometrial cancer and unlikely to use FMH for menopause. We therefore restricted the analysis of FMH use to women who were a) 40 years or older, b) had known menopausal status, and c) did not report current use of OCs. Each type of FMH (estrogen-only, estrogen plus progestin, and progestin-only) was analyzed separately, restricted to person-years contributed by women who used only that one type, compared to women who did not report any FMH use (estrogen-only, estrogen plus progestin, progestin-only, or unknown type). Few women (2,159 women, 17,099 person-years, 3 cases) switched from one FMH type to another, so we did not perform separate analyses in these women.

Obesity is strongly associated with endometrial cancer, can affect steroid hormone levels through the action of aromatase, and has been found to modify the associations of exogenous hormone use with endometrial cancer. We therefore repeated our analyses stratified by obesity (BMI ≥30 vs. <30 kg/m²).

Separate analyses were performed to investigate the association of type I and other histologic types endometrial cancers with exogenous hormone use, censoring all other incident cases that could not be classified at the time of diagnosis. In secondary analyses, we restricted case group to confirmed cases, censoring unconfirmed incident cases at the time of diagnosis, and repeated analyses censoring all prior cancers.

All analyses were conducted using SAS software, version 9.4 (SAS Institute, Inc., Cary, North Carolina).

RESULTS

We identified 300 endometrial cancer cases during 689,546 person-years of follow up. Mean length of follow-up was 14.5 years. Compared with never users of oral contraceptives, ever users at baseline were younger, more likely to be married, parous, and premenopausal (Table 1).

Oral Contraceptives

After adjustment for potential confounders, the IRR comparing ever with never use of OCs was 0.86 (95% CI=0.63, 1.18) (Table 2). IRRs for former and current use compared with never OC use were 0.87 (95% CI=0.64, 1.20) and 0.69 (95% CI=0.40, 1.20), respectively.

IRRs for 1-9, 10-19, 20-29, and ≥ 30 years since last use compared with never use were 0.69 (95% CI=0.44, 1.08), 0.85 (95% CI=0.54, 1.32), 0.98, (95% CI=0.66, 1.45) and 0.89, (95% CI=0.62, 1.28), respectively ($p_{\text{trend}}=0.43$). There was an inverse relation between duration of OC use and endometrial cancer risk. IRRs for 1-4, 5-9 and ≥ 10 years of use vs. never use 0.98 (95% CI=0.71, 1.35), 0.74 (95% CI=0.48, 1.13) and 0.45 (95% CI=0.27, 0.74), respectively ($p_{\text{trend}}=0.0002$). The inverse association between OC use and endometrial cancer risk among women who used OCs ≥ 5 years compared with never users changed little for up to 20 years since last use. The IRRs for <10 , 10-19 and ≥ 20 years since last use in such women were 0.45 (95% CI=0.26, 0.76), 0.51 (95% CI=0.26, 0.99), and 0.80 (95% CI=0.51, 1.24), respectively. There was little evidence for an association among women who used OCs for <5 years in any recency category.

The association between oral contraceptive use and endometrial cancer was confined to non-obese women (Table 3). The IRRs for current use compared to never use were 0.44 (95% CI=0.18, 1.07) and 0.98 (95% CI=0.48, 2.01) for non-obese and obese women, respectively. Compared to never users, the IRRs for former users were 0.70 (95% CI=0.42, 1.16) and 1.05 (95% CI=0.60, 1.59) among non-obese and obese women, respectively. The IRR for ≥ 10 years of use compared to never use was 0.19 (95% CI=0.07, 0.47) among non-obese women and 0.77 (95% CI=0.42, 1.41) among obese women.

We did not observe clear evidence of differences in the association of OC use with histologic subtypes of endometrial cancer (Supplemental Table 1). When analyses were restricted to confirmed endometrial cancer cases, the IRR for <5 years of OC use and discontinuation within the last 10 years (IRR=0.54, 95% CI=0.28, 1.06) was similar to ≥ 5 years of OC use with the same recency (IRR=0.55, 95% CI=0.29, 1.05) (Supplemental Table 2). In contrast, the IRR for <5 years of OC use and discontinuation within the last 10 years (IRR=1.00, 95% CI=0.52, 1.95) was closer to the null than for ≥ 5 years of OC use and discontinuation within the last 10 years (IRR=0.38, 95% CI=0.15, 0.98) in the main analysis. Estimates did not change substantially when non-endometrial cancers were censored (Supplemental Table 3).

Female Menopausal Hormones

The IRR for current use of estrogen-only FMH compared to never use of any FMH was 3.78 (95% CI=1.69, 8.43) (Table 4). There was little difference in the IRRs by duration of use 1-4 (IRR=1.25, 95% CI=0.70, 2.23, based on 13 cases) and ≥ 5 years (IRR=1.90, 95% CI=0.59, 6.09, based on 3 cases). No elevation was observed for former users (IRR=0.87, 95% CI=0.44, 1.72).

The IRR for ever users of estrogen plus progestin FMH relative to never users was IRR=0.82, (95% CI=0.52, 1.28) (Table 4). However, among current users the comparable IRR was 1.55, 95% CI=0.77, 3.11). In analyses of baseline data on the pattern of progestin use, risk was higher among users of sequential estrogen plus progestin FMH taking progestins <2 weeks/month (IRR=1.29, 95% CI=0.70, 2.39) and lower among continuous users of progestin (IRR=0.74, 95% CI=0.36, 1.50) compared with women who never used any FMH.

The IRRs comparing ever use of progestin-only FMH to never use was 1.51 (95% CI=0.73, 3.09, based on 8 cases) (Table 4).

While ever use compared to never use of estrogen-only FMH was associated with increased endometrial cancer risk among non-obese women (IRR=3.05, 95% CI=1.44, 6.46, 10 cases), this was not the case among obese women (IRR=0.99, 95% CI=0.44, 2.24, 7 cases) (Table 5). However, risk was similarly increased among non-obese and obese current users (IRR=5.05, 95% CI=1.42, 18.03 and IRR=5.16, 95% CI=1.51, 17.58, respectively, 4 cases in each group). The IRRs for ever use of estrogen plus progestin FMH were 1.00 (95% CI=0.47, 2.10) and 0.62 (95% CI=0.33, 1.19) among non-obese and obese women, respectively.

There was little evidence that the associations of FMH use with endometrial varied according to histologic subtypes (Supplemental Table 4).

Compared with the primary analysis, the association between progestin-only FMH use and endometrial cancer was attenuated when restricted to confirmed cancer cases (Supplemental Table 5). Associations of other variables with endometrial cancer were comparable between the main analysis and the analysis restricted to confirmed cases and when all non-endometrial cancers were censored (Supplemental Table 6).

DISCUSSION

In this prospective cohort study of U.S. black women, long term OC use was associated with reduced endometrial cancer risk in a dose-response manner. Current use of estrogen-only FMH was associated with increased risk, while former use was not appreciably associated with risk. Our results for estrogen plus progestin FMH suggested increased risk among current users but decreased risk among former users, although we had little data on pattern of progestin use and numbers of users were small.

According to the unopposed estrogen hypothesis (2), endometrial cancer risk is principally determined by the mitotic rate of endometrial cells, which is increased by estrogens in the absence of progesterone. Therefore the use of exogenous estrogens and progestins is likely to influence endometrial cancer risk.

Virtually every study of OC use and endometrial cancer risk has found an inverse association (3–13). A recent meta-analysis of 36 studies with 27,276 endometrial cancer cases found a summary odds ratio (OR) of 0.69 (95% CI=0.66, 0.73) for the association of ever vs. never OC use (32). This was lower, although not incompatible, with our result of 0.86 (95% CI=0.63, 1.17). Likewise, our finding of reduced risk with increasing lifetime duration of use was comparable to the meta-analysis of OCs with RRs of 0.81 (95% CI=0.76, 0.86), 0.64 (95% CI=0.59, 0.69), 0.52 (95% CI=0.47, 0.58) and 0.32 (95% CI=0.28, 0.38) for 1–4, 5–9, 10–14, and 15 years of use (32). It is likely, therefore, that our higher estimate of risk among ever users was attributable, in part, to the relatively low proportion of long-duration OC users in our study. We found only two studies, a pooled analysis of 11 U.S. studies (4 case-control and 7 cohort, 516 black cases) (5) and a case control study from South Africa (12) (524 total black cases) that examined the association of OC use and endometrial cancer

among black women. The results of both studies were comparable to findings among white women.

The majority of studies have found that users of estrogen-only FMH have a higher risk of endometrial cancer compared with never users of FMH (16–23). In our study, current users had over 3.75 times the risk of never FMH users, although former users were not at increased risk. Most previous studies have found increasing risk with increasing duration of use (18–20, 22, 23), although one small study did not (17). Prior studies have reported relative risks ranging from 2 to 10 among long term users (18–20, 22). Our estimates were consistent with increased risk with long term use, although they were based on few cases and imprecisely estimated.

The association of estrogen plus progestin FMH is complicated by different formulations and patterns of progestin use in these drugs (15). Sequential formulations, where estrogens are taken alone for a portion of a given month and progestins are taken for the remainder of the month, may increase risk (18, 19, 22–25), although one study observed no association (20). In contrast, most (4, 16, 20, 22–27) but not all (18, 19) studies have found that continuous combined estrogen plus progestin FMHs decrease risk. Our analysis of the baseline data on patterns of progestin use in FMH was consistent with this, although our estimates were imprecise. In our time-varying analysis, risk was lower among former users of estrogen plus progestin FMH compared with never users of FMH, but higher among current users. This may be attributable to random variation due to estimation based on a small number of cases. Additionally, it is difficult to compare our time-varying estrogen plus progestin FMH results with previous studies without knowing which types (sequential vs continuous) were being used by our current and former users after baseline.

Our data suggest that women who used progestin-only FMH were at increased risk of endometrial cancer. Progestin-only FMH are a standard treatment for endometrial hyperplasia (33). Lacey et al. found that, accounting for treatment, women seeking biopsy and diagnosed with any type of endometrial hyperplasia had four times the risk of endometrial cancer compared with those diagnosed with disordered proliferative endometrium, with RR ranging from 2.0 to 14.2 depending on presence of atypia (34). Women with atypical hyperplasia remained at substantially increased risk after 5 years. Although we lack data on this condition, our results are consistent with progestin-only FMH use being a marker for endometrial hyperplasia and thus the association with endometrial cancer may be due to confounding by indication.

Obesity has been reported to modify the associations of endometrial cancer with both oral contraceptives and FMH. Oral contraceptives have been found to be less protective in obese women (10, 35) although a large meta-analysis reported no modification (32). The positive association between estrogen-only FMH and endometrial cancer has likewise been reported reduced in obese women (16, 17, 20), while the inverse association with estrogen plus progestin FMH has been reported to be strongest among obese women (15, 16, 23). Obesity could alter the association of endometrial cancer with exogenous hormones because of differences in volume of distribution or pharmacokinetics (36). It has also been suggested that there is a threshold above which increased concentrations of estrogen do not further

increase the growth of endometrial tissue (2), which could reduce the impact of exogenous estrogens in obese women. Our results were consistent with a reduction of the protective effect of oral contraceptives in obese women and a protective effect of estrogen plus progestin FMH restricted to obese women. The strength of association between current use of estrogen only FMH and endometrial cancer was similar among obese and non-obese women.

We did not find compelling evidence for differences of associations of histologic subtypes of endometrial cancer with exogenous hormone use. The small numbers of cancers not classified as type I in our study limited our power to detect any potential differences in these associations, and combining these types may not be appropriate. Recent studies of risk factors for histologic subtypes have found little evidence of differences in associations with OC use between type I and II tumors (37) or FMH with type I, or II cancers (38).

Our study had a number of strengths. We analyzed data from a large prospective cohort study of self-identified black women. To the best of our knowledge, this is the first report of the association between FMH use and endometrial cancer incidence specifically in black women. We controlled for a large number of potential confounders, including anthropometric and reproductive factors.

There were several notable limitations. Foremost among them were the low prevalence of FMH use among women with an intact uterus and the high prevalence of short duration OC use, which resulted in limited power. Our OC analysis did not take into account changes that have occurred in these formulations over time. Hormone dosages have decreased over time, and a sequential formula which was associated with increased risk of endometrial cancer was used until 1979. However, prior studies have not found a large influence of dose on the overall effect of OC use and endometrial cancer (10, 13). Of greater concern are the limited data on the type of estrogen plus progestin FMH that were used. If sequential and continuous formulations had differing associations with endometrial cancer, it is likely to have attenuated our results to a degree which would depend on the mixture of sequential and continuous use in our study.

Our data are based on self-report. Thus, we would expect some degree of misclassification of exposure. As our data were collected prospectively, misclassification was most likely random. In the case of dichotomous exposures and in the extreme categories of polytomous categorical variables, we expect an attenuation of our results. We also included unconfirmed cases in our analysis, which may have resulted in misclassification of outcome. The inclusion of conditions whose associations with the exposures in this study differ from those of endometrial cancer in the case group could result in a differential bias whose direction would depend on the nature of those differences. However, estimated associations were generally similar to the results presented when we restricted analysis to confirmed cases. BWHS participants may differ from the U.S. black population as a whole in ways which could influence our results. This could limit generalizability of our findings to all black women.

We found that associations between use of exogenous hormones and endometrial cancer in black women are generally similar to what has been reported previously in white women. However, due to the low prevalence of FMH use and lack of data on the pattern of progestin use in estrogen plus progestin FMH users in our study, our finding on FMH use and endometrial cancer require confirmation in other studies.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by National Cancer Institute grants R01-CA58420 (principal investigator, L. Rosenberg; direct support, L. Adams-Campbell, J. Palmer, L. Rosenberg), UM1-CA164974 (principal investigator: L. Rosenberg; direct support, L. Adams-Campbell, J. Palmer, L. Rosenberg.), and R03-CA169888 (principal investigator: L. Wise; direct support, T. Sponholtz, L. Wise.) and National Institute of Health grant 1T32HL125232-01A1 (principal investigator: Vasani S. Ramachandran; direct support, T. Sponholtz).

We thank the participants and staff of the Black Women's Health Study as well as Drs. Sara Olson and Rie Adser Virkus for their feedback.

Data on endometrial cancer pathology were obtained from several state and district cancer registries (Arizona; California; Colorado; Connecticut; Delaware; Washington, DC; Florida; Georgia; Illinois; Indiana; Kentucky; Louisiana; Maryland; Massachusetts; Michigan; New Jersey; New York; North Carolina; Oklahoma; Pennsylvania; South Carolina; Tennessee; Texas; and Virginia). The study sponsors played no role in the study design, data collection, analyses, or interpretation of results, the preparation of the manuscript, or the decision to submit the manuscript for publication. The results reported here do not necessarily represent the views of the National Cancer Institute, or the respective state cancer registries.

Abbreviations

BMI	body mass index
BWHS	Black Women's Health Study
CI	confidence interval
FMH	female menopausal hormones
ICD-O	International Classification of Diseases for Oncology
IRR	incidence rate ratio
OC	oral contraceptive
OR	odds ratio

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. *CA Cancer J Clin.* 2015; 65(1):5–29. DOI: 10.3322/caac.21254 [PubMed: 25559415]
2. Key TJ, Pike MC. The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. *Br J Cancer.* 1988; 57(2):205–12. [PubMed: 3358913]

3. Combination oral contraceptive use and the risk of endometrial cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. *JAMA*. 1987; 257(6):796–800. [PubMed: 3027423]
4. Amankwah EK, Friedenreich CM, Magliocco AM, et al. Hormonal and reproductive risk factors for sporadic microsatellite stable and unstable endometrial tumors. *Cancer Epidemiol Biomarkers Prev*. 2013; 22(7):1325–31. DOI: 10.1158/1055-9965.EPI-13-0105 [PubMed: 23677572]
5. Cote ML, Alhajj T, Ruterbusch JJ, et al. Risk factors for endometrial cancer in black and white women: a pooled analysis from the epidemiology of endometrial cancer consortium (E2C2). *Cancer Causes Control*. 2015; 26(2):287–96. DOI: 10.1007/s10552-014-0510-3 [PubMed: 25534916]
6. Dossus L, Allen N, Kaaks R, et al. Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition. *Int J Cancer*. 2010; 127(2):442–51. DOI: 10.1002/ijc.25050 [PubMed: 19924816]
7. Hulka BS, Chambless LE, Kaufman DG, Fowler WC Jr, Greenberg BG. Protection against endometrial carcinoma by combination-product oral contraceptives. *JAMA*. 1982; 247(4):475–7. [PubMed: 7033575]
8. Kaufman DW, Shapiro S, Slone D, et al. Decreased risk of endometrial cancer among oral-contraceptive users. *N Engl J Med*. 1980; 303(18):1045–7. DOI: 10.1056/NEJM198010303031807 [PubMed: 7421893]
9. Levi F, La Vecchia C, Gulie C, et al. Oral contraceptives and the risk of endometrial cancer. *Cancer Causes Control*. 1991; 2(2):99–103. [PubMed: 1873443]
10. Maxwell GL, Schildkraut JM, Calingaert B, et al. Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk. *Gynecol Oncol*. 2006; 103(2):535–40. DOI: 10.1016/j.ygyno.2006.03.046 [PubMed: 16740300]
11. Tao MH, Xu WH, Zheng W, et al. Oral contraceptive and IUD use and endometrial cancer: a population-based case-control study in Shanghai, China. *Int J Cancer*. 2006; 119(9):2142–7. DOI: 10.1002/ijc.22081 [PubMed: 16823853]
12. Urban M, Banks E, Egger S, et al. Injectable and oral contraceptive use and cancers of the breast, cervix, ovary, and endometrium in black South African women: case-control study. *PLoS Med*. 2012; 9(3):e1001182.doi: 10.1371/journal.pmed.1001182 [PubMed: 22412354]
13. Voigt LF, Deng Q, Weiss NS. Recency, duration, and progestin content of oral contraceptives in relation to the incidence of endometrial cancer (Washington, USA). *Cancer Causes Control*. 1994; 5(3):227–33. [PubMed: 8061170]
14. Trapido EJ. A prospective cohort study of oral contraceptives and cancer of the endometrium. *Int J Epidemiol*. 1983; 12(3):297–300. [PubMed: 6629618]
15. Brinton LA, Felix AS. Menopausal hormone therapy and risk of endometrial cancer. *J Steroid Biochem Mol Biol*. 2014; 142:83–9. DOI: 10.1016/j.jsbmb.2013.05.001 [PubMed: 23680641]
16. Beral V, Bull D, Reeves G, Million Women Study C. Endometrial cancer and hormone-replacement therapy in the Million Women Study. *Lancet*. 2005; 365(9470):1543–51. DOI: 10.1016/S0140-6736(05)66455-0 [PubMed: 15866308]
17. Epstein E, Lindqvist PG, Olsson H. A population-based cohort study on the use of hormone treatment and endometrial cancer in southern Sweden. *Int J Cancer*. 2009; 125(2):421–5. DOI: 10.1002/ijc.24284 [PubMed: 19326453]
18. Razavi P, Pike MC, Horn-Ross PL, Templeman C, Bernstein L, Ursin G. Long-term postmenopausal hormone therapy and endometrial cancer. *Cancer Epidemiol Biomarkers Prev*. 2010; 19(2):475–83. DOI: 10.1158/1055-9965.EPI-09-0712 [PubMed: 20086105]
19. Lacey JV Jr, Brinton LA, Lubin JH, Sherman ME, Schatzkin A, Schairer C. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women. *Cancer Epidemiol Biomarkers Prev*. 2005; 14(7):1724–31. DOI: 10.1158/1055-9965.EPI-05-0111 [PubMed: 16030108]
20. Strom BL, Schinnar R, Weber AL, et al. Case-control study of postmenopausal hormone replacement therapy and endometrial cancer. *Am J Epidemiol*. 2006; 164(8):775–86. DOI: 10.1093/aje/kwj316 [PubMed: 16997897]
21. Allen NE, Tsilidis KK, Key TJ, et al. Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation Into Cancer

- and Nutrition. *Am J Epidemiol.* 2010; 172(12):1394–403. DOI: 10.1093/aje/kwq300 [PubMed: 20961969]
22. Trabert B, Wentzensen N, Yang HP, et al. Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk? *Int J Cancer.* 2013; 132(2):417–26. DOI: 10.1002/ijc.27623 [PubMed: 22553145]
 23. Doherty JA, Cushing-Haugen KL, Saltzman BS, et al. Long-term use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer. *Am J Obstet Gynecol.* 2007; 197(2):139 e1–7. DOI: 10.1016/j.ajog.2007.01.019 [PubMed: 17689625]
 24. Jaakkola S, Lyytinen HK, Dyba T, Ylikorkala O, Pukkala E. Endometrial cancer associated with various forms of postmenopausal hormone therapy: a case control study. *Int J Cancer.* 2011; 128(7):1644–51. DOI: 10.1002/ijc.25762 [PubMed: 21280035]
 25. Reed SD, Voigt LF, Beresford SA, Hill DA, Doherty JA, Weiss NS. Dose of progestin in postmenopausal-combined hormone therapy and risk of endometrial cancer. *Am J Obstet Gynecol.* 2004; 191(4):1146–51. DOI: 10.1016/j.ajog.2004.04.041 [PubMed: 15507934]
 26. Chlebowski RT, Anderson GL, Sarto GE, et al. Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial. *J Natl Cancer Inst.* 2016; 108(3):doi: 10.1093/jnci/djv350
 27. Phipps AI, Doherty JA, Voigt LF, et al. Long-term use of continuous-combined estrogen-progestin hormone therapy and risk of endometrial cancer. *Cancer Causes Control.* 2011; 22(12):1639–46. DOI: 10.1007/s10552-011-9840-6 [PubMed: 21909949]
 28. Rosenberg L, Adams-Campbell L, Palmer JR. The Black Women's Health Study: a follow-up study for causes and preventions of illness. *J Am Med Womens Assoc.* 1995; 50(2):56–8.
 29. Palmer JR, Adams-Campbell LL, Boggs DA, Wise LA, Rosenberg L. A prospective study of body size and breast cancer in black women. *Cancer Epidemiol Biomarkers Prev.* 2007; 16(9):1795–802. DOI: 10.1158/1055-9965.EPI-07-0336 [PubMed: 17855697]
 30. Cox DR. Regression models and life-tables. *Journal of the Royal Statistical Society.* 1972; 34(2): 187–220.
 31. Andersen PK, Gill R. D. Cox's regression model for counting processes: a large sample study. *The Annals of Statistics.* 1982; 10(4):1100–20.
 32. Collaborative Group on Epidemiological Studies on Endometrial C. Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. *Lancet Oncol.* 2015; 16(9):1061–70. DOI: 10.1016/S1470-2045(15)00212-0 [PubMed: 26254030]
 33. Chandra V, Kim JJ, Benbrook DM, Dwivedi A, Rai R. Therapeutic options for management of endometrial hyperplasia. *J Gynecol Oncol.* 2016; 27(1):e8.doi: 10.3802/jgo.2016.27.e8 [PubMed: 26463434]
 34. Lacey JV Jr, Ioffe OB, Ronnett BM, et al. Endometrial carcinoma risk among women diagnosed with endometrial hyperplasia: the 34-year experience in a large health plan. *Br J Cancer.* 2008; 98(1):45–53. DOI: 10.1038/sj.bjc.6604102 [PubMed: 18026193]
 35. Henderson BE, Casagrande JT, Pike MC, Mack T, Rosario I, Duke A. The epidemiology of endometrial cancer in young women. *Br J Cancer.* 1983; 47(6):749–56. [PubMed: 6860544]
 36. Edelman AB, Carlson NE, Cherala G, et al. Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity. *Contraception.* 2009; 80(2):119–27. DOI: 10.1016/j.contraception.2009.04.011 [PubMed: 19631786]
 37. Setiawan VW, Yang HP, Pike MC, et al. Type I and II endometrial cancers: have they different risk factors? *J Clin Oncol.* 2013; 31(20):2607–18. JCO.2012.48.2596 [pii]. DOI: 10.1200/JCO.2012.48.2596 [PubMed: 23733771]
 38. Brinton LA, Felix AS, McMeekin DS, et al. Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. *Gynecol Oncol.* 2013; 129(2):277–84. S0090-8258(13)00094-2 [pii]. DOI: 10.1016/j.ygyno.2013.02.023 [PubMed: 23485770]

Table 1Age-standardized baseline characteristics^a of 47,555 participants in the Black Women's Health Study

	Oral contraceptive use	
	Ever	Never
Age, mean (SD)	36.6 (116.5)	39.2 (170.8)
Education, %		
<High school	1.8	4.3
High school	13.5	17.0
College	24.4	22.8
Graduate	21.9	21.4
Marital status, %		
Single	37.2	48.7
Married/living together	39.1	29.3
Separated/Divorced/Widowed	22.8	20.9
Age at menarche	12.3 (20.8)	12.3 (22.0)
History of infertility, %	10.0	9.8
Parous, %	63.4	50.3
Postmenopausal, %	8.2	22.0
Body mass index (kg/m ²)	29.0 (93.1)	30.5 (109.8)
Vigorous Physical Activity, hours/week, %		
1-4	53.0	47.5
5	13.3	12.2
Ever use of estrogen-only FMH, % ^b	2.6	3.4
Ever use of estrogen+progestin FMH, % ^b	8.7	9.0
Ever use of progestin-only female hormones, % ^b	1.6	1.1

Abbreviations: FMH (female menopausal hormones)

^aValues are means (SD) or percentages and are standardized to the age distribution of the study population.^bAmong women age ≥ 40 years and not taking oral contraceptives

Table 2

Association of Endometrial Cancer with Oral Contraceptive Use, 1995-2013

Exposure	Cases	Person-years	Rate ^c	Age-adjusted ^d		Multivariable adjusted ^b	
				IRR	95% CI	IRR	95% CI
Oral contraceptive use							
Never	57	79,594	71.6	1.00	Ref.	1.00	Ref.
Ever	243	609,906	39.8	0.72	0.53, 0.98	0.86	0.63, 1.18
Former	221	489,406	45.2	0.74	0.54 1.00	0.87	0.64, 1.20
Years since last use ^d							
1-9	40	174,341	22.9	0.52	0.34, 0.80	0.69	0.44, 1.08
10-19	38	134,455	28.3	0.72	0.46, 1.13	0.85	0.54, 1.32
20-29	58	105,042	55.2	0.85	0.58, 1.26	0.98	0.66, 1.45
30	77	62,163	123.9	0.79	0.55, 1.14	0.89	0.62, 1.28
Current	22	120,500	18.3	0.61	0.36, 1.03	0.69	0.40, 1.20
Duration (years)							
1-4	165	325,167	50.7	0.84	0.61, 1.15	0.98	0.71, 1.35
5-9	42	142,583	29.5	0.59	0.39, 0.90	0.74	0.48, 1.13
10	24	122,339	19.6	0.37	0.22, 0.60	0.45	0.27, 0.74
				P _{trend}	<0.0001	P _{trend}	0.0002
Recency (years) × Duration (years) ^e							
<10, <5	36	118,125	30.5	0.74	0.48, 1.14	0.91	0.58, 1.45
<10, 5	22	168,133	13.1	0.34	0.20, 0.58	0.45	0.26, 0.76
10-19, <5	27	76,367	35.4	0.96	0.59, 1.58	1.09	0.66, 1.80
10-19, 5	11	58,087	18.9	0.41	0.21, 0.80	0.51	0.26, 0.99
20, <5	102	129,808	78.6	0.85	0.60, 1.18	0.95	0.68, 1.34
20, 5	33	37,397	88.2	0.69	0.45, 1.08	0.80	0.51, 1.25

Abbreviations: CI, confidence interval; IRR, incidence rate ratio.

^a Age adjusted model stratified by age and study period^b Multivariable model stratified by age and study period and adjusted for age at menarche, parity, menopausal status, estrogen-only FMH use, estrogen plus progestin FMH use, smoking, body mass index, and vigorous physical activity.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

^cCrude rate per 100,000 person-years
^dYears since last use (P_{trend}=0.03 (age- and period adjusted), 0.43 (multivariable adjusted))
^eCross-tabulated recency and duration of use

Table 3

Association of Endometrial Cancer with Oral Contraceptive Use, Stratified by Obesity Status 1995-2013

	Non obese (BMI <30 kg/m ²)				Obese (BMI ≥30 kg/m ²)			
	Cases	Rate ^c	IRR	95% CI	Cases	Rate ^c	IRR	95% CI
Oral contraceptive use								
Never	23	49.4	1.00	Referent	33	103.5	1.00	Referent
Ever	96	25.2	0.68	0.41, 1.13	145	64.8	1.05	0.69, 1.58
Former	88	29.7	0.70	0.42, 1.16	131	69.5	1.05	0.69, 1.59
Years since last use								
1-9	15	13.3	0.47	0.23, 0.97	25	41.6	0.96	0.54, 1.72
10-19	18	22.2	0.71	0.36, 1.41	20	38.3	0.97	0.53, 1.78
20-29	28	46.3	0.94	0.51, 1.72	30	68.8	1.03	0.61, 1.76
30	23	67.9	0.64	0.34, 1.18	52	189.1	1.12	0.70, 1.78
Current	8	9.5	0.44	0.18, 1.07	14	39.8	0.98	0.48, 2.01
Duration (years)								
1-4	68	34.5	0.86	0.51, 1.43	95	76.3	1.11	0.73, 1.70
5-9	17	18.7	0.55	0.28, 1.07	25	49.6	0.95	0.55, 1.65
10	6	7.5	0.19	0.07, 0.47	18	43.7	0.77	0.42, 1.41

Abbreviations: BMI, body mass index; CI, confidence interval; IRR, incidence rate ratio.

^a Age adjusted model stratified by age and study period.^b Multivariable model stratified by age and study period and adjusted for age at menarche, parity, menopausal status, estrogen-only FMH use, estrogen plus progestin FMH use, smoking, body mass index, (continuous), and vigorous physical activity.^c Crude rate per 100,000 person-years.

Association of Female Menopausal Hormone Use with Endometrial Cancer Among Women Aged 40 years, 1995-2013^a

Table 4

Exposure	Cases	Person-years	Rate ^d	Age-adjusted ^b		Multivariable adjusted ^c	
				IRR	95% CI	IRR	95% CI
Estrogen only FMH use ^e							
Never ^f	155	277,471	55.9	1.00	Ref.	1.00	Ref.
Ever	16	12,130	131.9	1.28	0.76, 2.17	1.32	0.78, 2.23
Former	9	8,882	101.3	0.86	0.44, 1.70	0.87	0.44, 1.72
Years since last use							
1-9	5	6,230	80.3	0.71	0.29, 1.73	0.73	0.30, 1.80
10	4	2,637	151.7	1.19	0.43, 3.26	1.15	0.42, 3.17
Current	7	3,248	215.5	3.45	1.56, 7.65	3.78	1.69, 8.43
Duration (years)							
1-4	13	10,668	121.9	1.22	0.68, 2.16	1.25	0.70, 2.23
5	3	1,271	236.0	1.85	0.58, 5.89	1.90	0.59, 6.09
Estrogen + progestin FMH use ^g							
Never ^f	155	277,471	55.9	1.00	Ref.	1.00	Ref.
Ever	25	28,602	87.4	0.71	0.46, 1.11	0.82	0.53, 1.28
Former	15	17,790	84.3	0.55	0.32, 0.96	0.63	0.36, 1.09
Years since last use							
1-9	9	13,586	66.2	0.46	0.23, 0.92	0.53	0.27, 1.06
10	6	4,180	143.5	0.79	0.34, 1.83	0.86	0.37, 2.01
Current	10	10,812	92.5	1.29	0.65, 2.56	1.55	0.78, 3.11
Duration							
1-4	16	20,356	78.6	0.71	0.42, 1.20	0.79	0.47, 1.35
5	9	7,304	123.2	0.81	0.41, 1.61	0.99	0.49, 1.98
Pattern of progestin Use ^g							
Never used FMH ^f	177	186,113	95.1	1.00	Ref.	1.00	Ref.
<2 wk/mo.	11	7,836	140.4	1.14	0.62, 2.11	1.29	0.70, 2.39
2-3 wk/mo.	0	5,080	0.0	0.00	-	0.00	-

Exposure	Cases	Person-years	Rate ^d	Age-adjusted ^b		Multivariable adjusted ^c	
				IRR	95% CI	IRR	95% CI
Continuous	8	9,442	84.7	0.64	0.31, 1.31	0.74	0.36, 1.50
Other	1	1,390	71.9	0.62	0.09, 4.44	0.63	0.09, 4.49
Progestin only FMH Use ^{e,g}							
Never ^f	155	277,471	55.9	1.00	Ref.	1.00	Ref.
Ever	8	7,366	108.6	1.74	0.85, 3.56	1.51	0.73, 3.09

Abbreviations: CI, confidence interval; IRR, incidence rate ratio; FMH, female menopausal hormones.

^a Analysis restricted to women 40 years of age, not taking oral contraceptives, with known menopause status, and not reporting use of multiple FMH types.

^b Age adjusted model stratified by age and study period.

^c Multivariable model stratified by age and study period and adjusted for age at menarche, parity, menopausal status, oral contraceptive use, smoking, body mass index, and vigorous physical activity.

^d Crude rate per 100,000 person-years.

^e Additionally adjusted for estrogen plus progestin FMH use.

^f Never reported any FMH use.

^g Additionally adjusted for estrogen-only FMH use.

Association of Female Menopausal Hormone Use with Endometrial Cancer Among Women Aged 40 years, Stratified by Obesity Status, 1995-2013^a**Table 5**

	Non obese (BMI <30 kg/m ²)				Obese (BMI ≥30 kg/m ²)			
	Cases	Rate	IRR	95% CI	Cases	Rate	IRR	95% CI
Estrogen only FMH use ^e								
Never ^f	32	65.4	1.00	Referent	71	188.4	1.00	Referent
Ever	10	173.7	3.05	1.44, 6.46	7	172.9	0.99	0.44, 2.24
Former	6	156.8	2.50	1.01, 6.17	3	99.2	0.50	0.15, 1.63
Current	4	207.3	5.05	1.42, 18.03	4	389.9	5.16	1.51, 17.58
Estrogen + progestin FMH use ^g								
Never ^f	32	65.4	1.00	Referent	71	188.4	1.00	Referent
Ever	11	63.6	1.00	0.47, 2.10	12	121.1	0.62	0.33, 1.19
Former	5	51.4	0.73	0.27, 1.94	10	156.0	0.65	0.33, 1.30
Current	6	79.5	1.65	0.55, 4.93	2	57.2	0.48	0.09, 2.47

Abbreviations: BMI, body mass index; CI, confidence interval; IRR, incidence rate ratio; FMH, female menopausal hormones.

^aAnalysis restricted to women 40 years of age, not taking oral contraceptives, with known menopause status, and not reporting use of multiple FMH types.^bAge adjusted model stratified by age and study period.^cMultivariable model stratified by age and study period and adjusted for age at menarche, parity, menopausal status, oral contraceptive use, smoking, body mass index (continuous), and vigorous physical activity.^dCrude rate per 100,000 person-years.^eAdditionally adjusted for estrogen plus progestin FMH use.^fNever reported any FMH use.^gAdditionally adjusted for estrogen-only FMH use.